In vivo and ex vivo/in vitro pharmacodynamic evaluation is the key to the pre-clinical research of cell therapy, with in vivo pharmacodynamic experiments being the most critical and difficult to surmount. As a research and development hotspot of cell therapy, the pharmacodynamic evaluation of CAR-T cells is quite different from that of traditional small molecule drugs because of the complexity of the mechanism of CAR-T cells. For example, researchers must determine whether CAR-T cells can effectively bind to predetermined targets to kill target cells, the distribution and duration of CAR-T cells in the body, and much more.
Our Pharmacodynamic Evaluation Services
In vitro pharmacodynamic evaluation
|In vitro killing activity test of CAR-T cell|
|ADCC/CDC/CTL cytotoxicity test|
|Immune cell phenotype analysis|
In vivo pharmacodynamic evaluation
|CAR-T cell proliferation monitoring in vivo|
|Pharmacodynamic evaluation of CDX models|
|Analysis of lymphocytic infiltration|
Killing activity test results of CAR-T cells
FMC63 CAR-T cells and T cells with different effective target ratios were incubated with Nalm6 cells separately for 48 hours, and then the tumor cell apoptosis was detected by flow cytometry. As shown in the figure, compared with the T cell group, with the conditions of different effective target ratios, FMC63 CAR-T cells all exhibited significantly enhanced specific cytotoxicity to Nalm6 cells.
Figure. 2 The detection result of the positive rate of CD19 antigen on the surface of Nalm6 cells and the test result of the killing of Nalm6 tumor cells by FMC63 CAR-T cells.
Inquiries and Quote Requests